Zhejiang CONBA Pharmaceutical Co.,Ltd.
Shanghai Stock ExchangeTotal Valuation
Zhejiang CONBA Pharmaceutical Co.,Ltd. carries a market capitalization of 10.48B, placing it among publicly traded companies globally. Its enterprise value stands at 10.59B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 10.48B |
| Enterprise Value | 10.59B |
Share Statistics
Zhejiang CONBA Pharmaceutical Co.,Ltd. currently has 2.58B shares outstanding.
| Shares Outstanding | 2.58B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Zhejiang CONBA Pharmaceutical Co.,Ltd. trades at a trailing price-to-earnings ratio of 18.63. The price-to-sales ratio is 1.72, and the price-to-book ratio stands at 1.80.
| PE Ratio | 18.63 |
| PS Ratio | 1.72 |
| PB Ratio | 1.80 |
| P/TBV Ratio | 1.74 |
| P/FCF Ratio | 52.89 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Zhejiang CONBA Pharmaceutical Co.,Ltd. trades at an EV/EBITDA multiple of 16.52 and an EV/FCF ratio of 41.73. The EV/Sales ratio of 1.65 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 16.52 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.65 |
| EV / EBITDA | 16.52 |
| EV / EBIT | 16.52 |
| EV / FCF | 41.73 |
Financial Position
Zhejiang CONBA Pharmaceutical Co.,Ltd. maintains a current ratio of 1.78, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.37, indicating elevated leverage, while an interest coverage ratio of 61.93 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.78 |
| Quick Ratio | 0.35 |
| Debt / Equity | 4.37 |
| Debt / EBITDA | 0.47 |
| Interest Coverage | 61.93 |
Financial Efficiency
Zhejiang CONBA Pharmaceutical Co.,Ltd. posts a return on equity of 9.71 and a return on invested capital of 7.25.
| Return on Equity (ROE) | 9.71 |
| Return on Assets (ROA) | 5.92 |
| Return on Invested Capital (ROIC) | 7.25 |
| Return on Capital Employed (ROCE) | 8.62 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.48 |
Taxes
Over the trailing twelve months, Zhejiang CONBA Pharmaceutical Co.,Ltd. has paid 113.37M in income taxes, reflecting an effective tax rate of 15.62.
| Income Tax | 113.37M |
| Effective Tax Rate | 15.62 |
Stock Price Statistics
Zhejiang CONBA Pharmaceutical Co.,Ltd.'s stock has declined approximately -7.19101% over the past 52 weeks. The 50-day moving average sits at 4.23, while the 200-day moving average is 4.44.
| Beta (5Y) | N/A |
| 52-Week Price Change | -7.19101% |
| 50-Day Moving Average | 4.23 |
| 200-Day Moving Average | 4.44 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Zhejiang CONBA Pharmaceutical Co.,Ltd. generated 6.43B in revenue and converted that into 593.83M in net income, yielding earnings per share of 0.21. EBITDA reached 641.25M, while operating income came in at 641.25M.
| Revenue | 6.43B |
| Gross Profit | 3.38B |
| Operating Income | 641.25M |
| Pretax Income | 725.73M |
| Net Income | 593.83M |
| EBITDA | 641.25M |
| EBIT | 641.25M |
| Earnings Per Share (EPS) | 0.21 |
Balance Sheet
Zhejiang CONBA Pharmaceutical Co.,Ltd. holds 872.85M in cash and equivalents against 302.29M in total debt, resulting in a net debt position of -671.21M. Total book value stands at 6.16B, with working capital of 1.93B providing operational flexibility.
| Cash & Cash Equivalents | 872.85M |
| Total Debt | 302.29M |
| Net Debt | -671.21M |
| Equity (Book Value) | 6.16B |
| Book Value Per Share | 2.44 |
| Working Capital | 1.93B |
Cash Flow
After subtracting -245.07M in capital expenditures, free cash flow totaled -245.07M - equivalent to -0.10 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -245.07M |
| Free Cash Flow | -245.07M |
| FCF Per Share | -0.10 |
Margins
Zhejiang CONBA Pharmaceutical Co.,Ltd. operates with a gross margin of 52.53, reflecting its pricing power and cost economics. The operating margin of 9.98 and net profit margin of 9.24 provide insight into operational efficiency.
| Gross Margin | 52.53 |
| Operating Margin | 9.98 |
| Pretax Margin | 11.30 |
| Profit Margin | 9.24 |
| EBITDA Margin | 9.98 |
Dividends & Yields
The company's payout ratio of 61.55 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.15 |
| Dividend Yield | N/A |
| Payout Ratio | 61.55 |
| Shareholder Yield | 9.35 |
| FCF Yield | 1.89 |
Stock Splits
Zhejiang CONBA Pharmaceutical Co.,Ltd.'s most recent stock split took place on June 15, 2016 with a 2:3 split ratio.
| Last Split Date | 6/15/2016 |
| Split Ratio | 2:3 |
Scores
Zhejiang CONBA Pharmaceutical Co.,Ltd. posts an Altman Z-Score of 4.00, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.00 |